Carboxylated osteocalcin for treatment of amyloidosis or diseases associated with abnormal protein folding
AssigneeNational Institute of Immunology
InventorsSarika GUPTA, Viji VIJAYAN, Ibrar Ahmed SIDDIQUE
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to improved compositions that are effective in management of disorders caused by pathogenic amyloid deposits. The disclosure discloses a composition comprising carboxylated osteocalcin which is effective in therapeutic clearance of abnormal amyloid deposits.
Claims14
A composition comprising carboxylated osteocalcin as represented by SEQ ID NO:
- 1, for use in treatment of amyloid deposits.
A composition comprising carboxylated osteocalcin as represented by SEQ ID NO:
- 1, for use in protection of a tissue component in an amyloid diseased mammal, wherein the tissue component is blood brain barrier comprising endothelial cells.
A composition comprising carboxylated osteocalcin as represented by SEQ ID NO:
- 1, for use in reducing cleavage and phosphorylation of abnormal Tau protein in brain.
A composition comprising carboxylated osteocalcin as represented by SEQ ID NO:
- 1, for use in increasing expression of undercarboxylated osteocalcin in circulation.
Dependencies are inferred from the claim text.